首页> 美国卫生研究院文献>Future Science OA >Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression
【2h】

Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression

机译:肝纤维化:关于生物标志物状态及其在疾病进展中的意义的汇编

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Liver fibrosis occurs in response to different etiologies of chronic liver injury. Diagnosing degree of liver fibrosis is a crucial step in evaluation of severity of the disease. An invasive liver biopsy is the gold standard method associated with pain and complications. Biomarkers to detect liver fibrosis include direct markers of extracellular matrix turnover and indirect markers as a reflection of liver dysfunction. Although a single marker may not be useful for successful management, a mathematical equation combining tests might be effective. The main purpose of this review is to understand the diagnostic accuracy of biomarkers and scoring systems for liver fibrosis. Advances in -omics approach have generated clinically significant biomarker candidates for liver fibrosis that need further evaluation.
机译:肝纤维化是根据慢性肝损伤的不同病因而发生的。肝纤维化的诊断程度是评估疾病严重程度的关键步骤。侵入性肝活检是与疼痛和并发症相关的金标准方法。检测肝纤维化的生物标志物包括细胞外基质更新的直接标志物和反映肝功能障碍的间接标志物。尽管单个标记对于成功的管理可能没有用,但是结合测试的数学方程可能是有效的。这篇综述的主要目的是了解肝纤维化的生物标志物和评分系统的诊断准确性。组学方法的进步为肝纤维化产生了临床上重要的生物标志物候选物,需要进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号